Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01274481 · ClinicalTrials.gov registry record · Phase 1

Iloprost Effects on Gas Exchange and Pulmonary Mechanics

A Phase 1 study of Pulmonary Hypertension and Acute Respiratory Distress Syndrome, sponsored by University of Oklahoma.

Completed
Registry status
Phase 1
Development phase
20
Enrollment target
1
Study location

NCT01274481 is a Phase 1 study of Pulmonary Hypertension and Acute Respiratory Distress Syndrome that has completed, run by University of Oklahoma. The registered enrollment target is 20 participants, below the 613-participant average among 72 other Pulmonary Hypertension trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01274481, a Phase 1 study of Pulmonary Hypertension and Acute Respiratory Distress Syndrome, has completed, sponsored by University of Oklahoma.

COMPLETED
Registry status
Phase 1
Development phase
20 participants
Enrollment target
1
Study location

Study Summary

This study will examine the hypothesis that iloprost maintains and improves ventilation perfusion matching in patients with pulmonary hypertension and ARDS/ALI as reflected by 1) an improved PaO2/FIO2 ratio as calculated from the measured arterial blood gases obtained before and after iloprost administration, 2) an improvement in lung compliance, and 3) an improvement in the ventilatory equivalents for oxygen and CO2 measured by expired gas analysis.

Interventions

  • DRUG Iloprost

Study Locations (1)

Oklahoma

  • OU Medical Center - Oklahoma City

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2011-03
Est. Completion 2012-07
Phase Phase 1

Sponsor

University of Oklahoma

358 total trials

What the Registry Record Tells You About NCT01274481

The ClinicalTrials.gov registry entry for NCT01274481 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 613-participant average among 72 other Pulmonary Hypertension trials with a reported enrollment target (97% lower). The listed sponsor is University of Oklahoma, which has 358 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Pulmonary Hypertension appearing as the primary indexed condition, and to 1 intervention - of which Iloprost is the first listed.

NCT01274481 reports 1 study location spanning 1 distinct geographic area - top geographies include Oklahoma.

Frequently Asked Questions

What is clinical trial NCT01274481 about?

NCT01274481 is a clinical study titled "Iloprost Effects on Gas Exchange and Pulmonary Mechanics". This study will examine the hypothesis that iloprost maintains and improves ventilation perfusion matching in patients with pulmonary hypertension and ARDS/ALI as reflected by 1) an improved PaO2/FIO2 ratio as calculated from the measured arterial blood gases obtained before and after iloprost admin...

What is the current status of trial NCT01274481?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2011-03. Estimated completion is 2012-07.

What conditions does trial NCT01274481 study?

This clinical trial studies the following conditions: Pulmonary Hypertension, Acute Respiratory Distress Syndrome, Acute Lung Injury.

What interventions are being tested in trial NCT01274481?

The interventions under investigation include: Iloprost (DRUG).

Who is sponsoring clinical trial NCT01274481?

This trial is sponsored by University of Oklahoma, which has 358 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01274481 being conducted?

This trial has 1 study location across Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Pulmonary Hypertension

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.